LPCUF (Lee's Pharmaceutical Holdings) Moat Score: 0/10 (As of Jul. 08, 2026)


LPCUF Lee's Pharmaceutical Holdings Ltd LPCUF
72 GF Score
Price $0.19
GF Value $0.30
! 5 Warning Signs
View Full Analysis

What is Lee's Pharmaceutical Holdings Moat Score?

Lee's Pharmaceutical Holdings has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Lee's Pharmaceutical Holdings has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Lee's Pharmaceutical Holdings might have No Moat - No discernible moat.

Lee's Pharmaceutical Holdings  (OTCPK:LPCUF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Lee's Pharmaceutical Holdings Moat Score Related Terms

LPCUF
72GF Score
Lee's Pharmaceutical Holdings Ltd LPCUF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lee's Pharmaceutical Holdings (LPCUF) Overvalued in 2026?

Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings stock appears to be undervalued. The current stock price of $0.19 is trading 36.6% below its estimated GF Value™ of $0.30.

Key valuation signals for LPCUF:

  • Moat Score: 0
  • GF Value™: $0.30 vs. price of $0.19 (36.6% below fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the LPCUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lee's Pharmaceutical Holdings Business Description

Other Exchanges 00950:Hong Kong
Address Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
72GF Score

Get the complete analysis for LPCUF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.19
Price
$0.30
GF Value